Keros Therapeutics Inc (KROS)
$18.83 -$0.67 (-3.64%) 10:50 PM 12/14/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$762.75M -
Day's Range
$17.67 - $21.05 -
Volume
1,796,438 -
52 Week Low / High
$15.67 - $73.00 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 12
- Strong Buy
- 3
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong Sell
- $88.86
- Target Price
Company News
-
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer — Oct 16th, 2024
Keros Therapeutics, Inc. LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patient...
-
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer — Oct 16th, 2024
Keros Therapeutics, Inc. LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patient...
-
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer — Oct 16th, 2024
Keros Therapeutics, Inc. LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patient...
-
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer — Oct 16th, 2024
Keros Therapeutics, Inc. LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patient...
-
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer — Oct 16th, 2024
Keros Therapeutics, Inc. LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patient...
-
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference — Sep 12th, 2024
Keros Therapeutics, Inc. LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patien...
-
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer — Oct 16th, 2024
Keros Therapeutics, Inc. LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patient...
-
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer — Oct 16th, 2024
Keros Therapeutics, Inc. LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patient...
-
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer — Oct 16th, 2024
Keros Therapeutics, Inc. LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patient...
Similar Stocks
Portfolio
Comprised of 1 portfolios